Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

77 results about "Lipoproteins Receptors" patented technology

The Low-Density Lipoprotein (LDL) Receptor (LDL-R) is a mosaic protein of 839 amino acids (after removal of 21-amino acid signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100, which is embedded in the outer phospholipid layer of LDL particles.

Improved rAAv vectors

Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions that specifically target mammalian cells, such as pancreatic islets cells, that express low-density lipoprotein receptors on their cell surface. The disclosed vectors comprise one or more polynucleotide sequences that express one or more mammalian polypeptides having therapeutic efficacy in the amelioration, treatment and / or prevention of AAT- or cytokine polypeptide deficiencies, such as for example in diabetes and related diseases, as well as a variety of autoimmune disorders including, for example, lupus and rheumatoid arthritis.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C—C motif chemokine 2, IgM, CA 19-9, IL-10, TNF-α, and myoglobin as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL

Fused imidazopyridine derivatives as antihyperlipidemic agents

A novel compound of the formula:wherein ring Q is an optionally substituted pyridine ring;One of R0, R1 and R2 is -Y0-Z0, and the other tow groups are a hydrogen, a halogen, an optionally substituted hydroxy group, a hydrocarbon group that may be an optionally substituted hydrocarbon group or an acyl group;Y0 is a bond or an optionally substituted bivalent hydrocarbon group;Z0 is a basic group which may be bonded via oxygen, nitrogen, -CO-, -CS-, -SO2N(R3)- (where R3 is hydrogen or an optionally substituted hydrocarbon group), or S(O)n (wherein n is to 0, 1 or 2);......... is a single bond or a double bond, or a salt thereof, which has an excellent LDL receptor up-regulating, blood-lipids lowering, blood-sugar lowering and diabetic complication-ameliorating activity.
Owner:TAKEDA PHARMA CO LTD

Novel piperidine derivative

InactiveUS20070078120A1Increase heightRegulating LDL receptor synthesisBiocideOrganic chemistryHydrogen atomLipoproteins Receptors
The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4, R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD

LDL receptor gene expression promoters

PCT No. PCT / JP98 / 01225 Sec. 371 Date Sep. 24, 1999 Sec. 102(e) Date Sep. 24, 1999 PCT Filed Mar. 23, 1998 PCT Pub. No. WO98 / 42686 PCT Pub. Date Oct. 1, 1998LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): wherein R1 is optionally substituted phenyl or heterocycle; R2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, or alkenyl; X is O, S or NR4; R3 is optionally substituted phenyl, naphthyl, aralkyl, 5- to 6-membered aromatic heterocycle, alkyl, cycloalkyl or alkenyl, provided that when X is NR4, then it may form an optionally substituted nitrogen-containing heterocycle, or a pharmaceutically acceptable salt thereof, which can increase the expression dose (the amount of mRNA) of LDL receptor gene, and thus increase the amount of LDL receptor, and reduce the serum cholesterol level, and are useful in the treatment of hyperlipidemia.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD +1

Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods

A method for enriching a population of somatic mammary stem cells or mammary tumor stem cells based on low-density lipoprotein receptor-related protein 6 (LRP6). Also included are methods for screening for LRP6 modulators, as well as methods for reducing Wnt signaling, for treating Wnt signaling-related diseases, for detecting mammary basal-like cells, for diagnosing basal-like breast cancer, and for inhibiting proliferation of a tumor expressing LRP6, and compositions thereof.
Owner:VAN ANDEL RES INST

Bionic nanocarrier for treating GBM (glioblastoma) and preparation method of bionic nanocarrier

The invention provides a bionic nanocarrier for treating GBM (glioblastoma) and a preparation method of the bionic nanocarrier and belongs to the field of biomedical engineering. According to the bionic nanocarrier for treating the GBM and the preparation method of the bionic nanocarrier, Ang-RBCm-CA / siRNA comprises Ang-RBCm (Ang (Angiopep-2) polypeptide modified red blood cell membrane) and citraconic anhydride grafted polylysine and polyethylenimine-siRNA compound (CA / siRNA). Ang-RBCm-CA / siRNA can effectively carry siRNA and protect siRNA against degradation. The Ang-RBCm-CA / siRNA has prolonged blood circulation time and high blood brain barrier penetrability, can be efficiently taken in by U87MG brain glial cells over-expressed by a low-density LPR (lipoprotein receptor) and can realizerapid charge conversion in endosome / lysosome, effectively release siRNA and effectively treat in-situ U87MG GBM.
Owner:HENAN UNIVERSITY

Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same

Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same. The cationic nanoparticle of the present invention could effectively be applied in treatment of cancer that overexpress LDL receptors.
Owner:KOREA ADVANCED INST OF SCI & TECH +1

Dual-mode immunoassay method of ovarian cancer tumor marker

The invention discloses a dual-mode immunoassay method of an ovarian cancer tumor marker. A sensing interface is constructed by taking a carbon nanohorn and copper nano-cluster functionalized mixed phase (anatase / rutile) titanium dioxide mesoscopic crystal as a substrate, therefore, a lipolysis activated lipoprotein receptor antibody (Ab) (an early ovarian cancer tumor marker antibody) is immobilized; a free lipolysis activated lipoprotein receptor (an early ovarian cancer tumor marker) can be specifically recognized and combined with the immobilized lipolysis activated lipoprotein receptor antibody to the sensing interface, so as to cause the weakening of a photocurrent signal of an electrode and weaken the capability of the electrode to catalyze and decompose hydrogen peroxide; and hydrogen peroxide solutions with different concentrations can also oxidize and reduce methylene blue so as to enable the methylene blue to present blue with different chromaticities. Based on the phenomenon, a dual-mode analysis method for the colorimetric and photoelectrochemical response of the lipolysis activated lipoprotein receptor can be established.
Owner:FUJIAN NORMAL UNIV

Influence of LRP cytoplasmic domain on Abeta production

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid beta-protein (Abeta). Methods for preventing or treating diseases wherein amyloid beta-protein (Abeta) is a major constituent of amyloid plaques or amyloidosis by interfering with production of Abeta are described, as is a high throughput assay for screening compounds that inhibit Abeta production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.
Owner:RGT UNIV OF CALIFORNIA

Tetrahydroisoquinoline derivative and application thereof

Provided are a tetrahydroisoquinoline derivative and an application thereof. The invention relates to a compound represented by the formula (V) and a preparation method and an application thereof in medicines. In particular, the invention relates to the derivative of the compound represented by the general formula (V) and a preparation method and the application thereof as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compound disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, and increases the expression of hepatic LDL receptors and inhibits the expression of PCSK9.
Owner:CHENGDU BESTCHIRALBIO LIMITED LIABILITY

Tetrahydropalmatine derivative and application thereof

The invention relates to a tetrahydropalmatine derivative and application thereof, a compound as shown in a formula (VI) and a preparation method thereof, and an application of the compound in medicine. Specifically, the invention relates to a derivative of the compound as shown in the general formula (VI) and a preparation method thereof, and an application of the derivative as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, diabetes type II, hyperglycemia, adiposis, or insulin resistance and metabolic syndrome. The compound disclosed by the invention also can reduce total cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides, and increases the expression of a liver LDL receptor and inhibits the expression of proprotein convertase subtilisin / kexin type 9 (PCSK9).
Owner:CHENGDU BESTCHIRALBIO LIMITED LIABILITY

Preparation and application of fusion protein for treating hypercholesteremia

The invention discloses a PCSK9-combined fusion protein which is represented by the following general formula: X-connecting peptide-Y-connecting peptide-Z-connecting peptide-IgG Fc segment, wherein X, Y and Z are EGF(A) region polypeptide mutants in LDL-R (low-density lipoprotein receptor), and the connecting peptide is (GGGGS)n. The fusion protein disclosed by the invention can be combined with the PCSK9 at high affinity to inhibit the PCSK9 from degrading the hepatocyte LDL-R and increase the intake of the hepatocytes for LDL-C, and thus, has obvious advantages and favorable prospects in the aspect of treating hypercholesteremia, familial hypercholesteremia and other diseases.
Owner:CHENGDU KANGHONG BIOTECH

Construction method of atherosclerosis vulnerable plaque mouse model

The invention discloses a construction method of an atherosclerosis vulnerable plaque mouse model. According to the method, a low-density lipoprotein receptor gene (LDLR) with heterozygous point mutation in a fibrillin-1 (Fbn1) gene is obtained through a hybridization method to knock out a mouse. According to the method, Fbn1C1039G+ / - point mutation is introduced into an LDLR- / - mouse genome for the first time, characteristics of two genotypes are combined, the method is simple and easy to implement, and vulnerable plaques with large lipid cores, a large number of inflammatory cells, typical thin fibrous caps, rich new blood vessels and the characteristics of plaque internal hemorrhage, vascular outward reconstruction and the like can be formed; the occurrence of acute cardiovascular and cerebrovascular events such as plaque rupture similar to that of the human body can be observed on the model. The method is high in model forming rate and good in repeatability, a good animal foundation is provided for medicine research and instrument consumable improvement, and a good platform is provided for exploring an atherosclerosis mechanism.
Owner:HARBIN MEDICAL UNIVERSITY

siRNA for inhibiting expression of human PCSK9 gene and application thereof

The invention discloses an siRNA sequence for specifically inhibiting the expression of a human protein convertase subtilisin 9 (PCSK9) target gene and an application thereof. The siRNA can be chemically synthesized, and can also be constructed into corresponding recombinant lentivirus or adeno-associated virus and the like according to the sequence of the siRNA. After human hepatoma carcinoma cell HepG2 and human normal hepatoma carcinoma cell LO2 are transfected by the siRNA or the virus, the expression of PCSK9 can be effectively inhibited; the protein level of a low-density lipoprotein receptor (LDLR) is increased; and the activity of the hepatoma carcinoma cell for taking in low-density lipoprotein (LDL) is remarkably enhanced. After the recombinant lentivirus is subjected to high-pressure caudal vein injection administration, the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in plasma of a hypercholesterolemia model mouse can be remarkably reduced. The siRNA or the recombinant virus or a modifier thereof can be used for preventing and / or treating diseases like hyperlipidemia, atherosclerosis, cardiovascular and cerebrovascular diseases, obesity, diabetes and nephropathy.
Owner:CHINA PHARM UNIV

A preparation method of colloidal gold-carbocyanine-low-density lipoprotein double-labeled probe

The invention relates to a method for preparing a colloidal gold-carbonylated cyanine-low-density lipoprotein (LDL) double-labeled probe, which is characterized in that two different tracers of colloidal gold and carbonylated cyanine (DiI) are used to label the same target protein Prepare double-labeled probes on the molecule, and use instruments and equipment to detect the functional activity of cell protein receptors. The preparation steps include: (1) extract and purify LDL; (2) prepare DiI-LDL; (3) prepare colloidal gold; (4) prepare Colloidal gold-DiI-LDL double-labeled probe; (5) Application of colloidal gold-DiI-LDL double-labeled probe. By improving the pH of the preparation environment, protein quantification and increasing the number of separations, the prepared colloidal gold-DiI-LDL double-labeled probe has the advantages of high yield, high purity, strong specificity, wide application range and rich detection methods. Laser confocal microscopy, flow cytometry and transmission electron microscopy and other instruments and equipment can accurately and efficiently detect the functional activity of cellular LDL receptors.
Owner:湖南康普医药研究院

Feed for aquarium fish

Feed for aquarium fish is prepared from, by mass, 20%-30% of wheat, 10%-20% of fish meal, 10%-20% of chicken liver meal, 10%-20% of silkworm chrysalis meal, 10%-20% of whole egg powder, 5%-10% of dried shrimp meal, 0.01%-1% of beta-carotene, 2%-3% of dehydrated spinach, 2%-3% of red yeast rice powder, 1%-2% of soybean petide and 0.5%-1% of 17 alpha-methyltestosterone which is purchased from Shanghai Yubo Bio-Technology Limited and is more than or equal to 98% in purity. The feed provides comprehensive and balanced nutrients for growth of the aquarium fish, and the 17 alpha-methyltestosterone activates LDL receptors on the surfaces of chromatophores at the same time, so that the lipoprotein uptake of the chromatophores is increased, the amount of carotenoid carried by lipoprotein and deposited in the chromatophores is increased, and the physical fitness and the body color of the aquarium fish are enhanced.
Owner:TIANJIN MODERN TIANJIAO AQUATIC FEED CO LTD

Optically active dibenzylamine derivative, and method for preparing thereof

Substantially optically pure (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, or a salt thereof, or a solvate thereof, which has actions of reducing amount of PCSK9 protein and increasing amount of LDL receptor.
Owner:KOWA CO LTD

Electrochemical luminescence kit for detecting anti-LRP4 antibody and manufacturing method thereof

The invention relates to a novel electrochemical luminescence kit for detecting a low-density lipoprotein receptor associated protein 4 (LRP4) antibody from a detected sample and a manufacturing method thereof. The manufactured kit comprises a streptavidin-coated magnetic bead particle working solution, a biotin-labeled LRP4 working solution, a terpyridyl ruthenium-labeled anti-human IgG antibodyworking solution, an anti-LRP4 antibody calibration product and / or quality control product working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the manufactured kit is electrochemiluminescence, a streptavidin-biotin biological reaction signal amplification system is used, a detection speed is high, sensitivity is high, a linear range is wide, detection result repeatability is good, and accurate quantitative detection of the anti-LRP4 antibody in a sample can be achieved.
Owner:江苏三联生物工程股份有限公司

Preparation method of atherosclerotic mouse model with NOD (Non-Obese Diabetic) genetic background

The invention relates to a preparation method of an atherosclerotic mouse model with NOD (Non-Obese Diabetic) genetic background, and belongs to the technical fields of genetic engineering and geneticmodification. For the first time, ApoE (Apolipoprotein E) and LDLR (Low-Density Lipoprotein Receptor) genes in a NOD genetic background mouse are knocked out at the same time to obtain a gene knockout mouse model, which can induce atherosclerotic atherosclerosis, of the NOD genetic background mouse. The aorta of the atherosclerotic mouse model with the NOD genetic background has obvious atherosclerotic plaque formation. Compared with the traditional classic atherosclerotic model C57B / L6 background ApoE gene knockout mouse, the atherosclerotic mouse model has consistent incidence degree. By adopting the method disclosed by the invention, a brand new atherosclerosis gene knockout mouse model with the NOD genetic background is provided for researchers, and is of great value for the basic theoretical research as well as clinical diagnosis and treatment of atherosclerosis.
Owner:XINXIANG MEDICAL UNIV

Tetrahydroberberine derivative and application thereof

The invention relates to a tetrahydroberberine derivative and application thereof and relates to a compound represented by a formula (V) shown in the description, a preparation method therefor and application of the compound in medicine. Particularly, the invention relates to a derivative of the compound represented by the general formula (V), a preparation method for the derivative of the compound and use of the derivative of the compound in the prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, fatty degeneration of liver, type II diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the invention can also be used for lowering total cholesterol, LDL (Low-Density Lipoprotein)-cholesterol and triglyceride, improving liver LDL receptor expression and inhibiting PCSK9 expression.
Owner:CHENGDU BESTCHIRALBIO LIMITED LIABILITY

Methods and compositions to lower plasma cholesterol levels

A method is disclosed for determining whether a compound binds to a lipoprotein such as LDL or VLDL in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compound to form a complex with the lipoprotein, e.g., LDL or VLDL, and then determining whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, is provided that includes the administration fo an effective amount of a compound which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.
Owner:埃瑟若詹尼克斯公司

Adsorbent for removing blood lipoprotein and preparation method thereof

The invention discloses an adsorbent for removing blood lipoprotein and a preparation method thereof. Firstly, in the presence of an initiator, a grafting monomer is grafted on the surface of an adsorption carrier to form a connecting arm containing an aldehyde group, then the aldehyde group and Schiff base of amino acid molecules react to form a short chain containing acidic amino acids and hydrophobic amino acids, and by controlling the carrier content of acidic amino acids and hydrophobic amino acids, an LDL receptor and Apo B100-like binding domain and LDL are combined to reduce non-specific adsorption. The side chain grafting method adopted in the invention can increase a large number of binding sites and effectively load amino acids, and the side chain also functions as a connectingarm, thereby effectively reducing steric hindrance during adsorption and greatly improving the adsorption effect. The synthesis is simple and convenient, the raw materials are cheap and easily available, and thus the adsorbent has wide application prospects.
Owner:佛山市博新生物科技有限公司

Hypolipidemic drug

The invention relates to the technical field of traditional Chinese medicine, in particular to a blood lipid-lowering agent, which is made of the following raw materials in parts by mass: 22-28 parts of Salvia miltiorrhiza, 22-28 parts of Polygala, 18-28 parts of Snake Grape, 18- 28 servings, 18-28 servings of hanging golden lanterns, 16-24 servings of Puhuang, 16-24 servings of radish seeds, 14-20 servings of cinnamon, 14-20 servings of Ligustrum lucidum, 10-20 servings of intermittent, 5-15 servings of Polygonum cuspidatum 5-15 parts of dandelion, 5-15 parts of scallion, 5-15 parts of elm money, 5-15 parts of garcinia cambogia, 5-7 parts of kudzu root, 5-7 parts of scutellaria chinensis, 3-5 parts of fennel. The blood lipid-lowering agent of the present invention can promote the transformation of cholesterol, promote the expression of LDL receptors on cell membranes, accelerate the decomposition of lipoproteins; activate lipoprotein metabolic enzymes, promote the hydrolysis of triglycerides; and promote the metabolism of other lipids ; It can effectively remove the cholesterol deposited on blood vessels, prevent platelet aggregation, and reduce the occurrence of heart disease.
Owner:张培君
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products